Skip to Content
Merck
  • Subtype-Directed Differentiation of Human iPSCs into Atrial and Ventricular Cardiomyocytes.

Subtype-Directed Differentiation of Human iPSCs into Atrial and Ventricular Cardiomyocytes.

STAR protocols (2020-10-29)
Mandy Kleinsorge, Lukas Cyganek
ABSTRACT

The generation of homogeneous populations of subtype-specific cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) is crucial in cardiovascular disease modeling as well as in drug discovery and cardiotoxicity screenings. This protocol describes a simple, robust, and efficient monolayer-based differentiation of hiPSCs into defined atrial and ventricular cardiomyocytes. For complete details on the use and execution of this protocol, please refer to Cyganek et al., 2018.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-α-Actinin (Sarcomeric) antibody produced in mouse, clone EA-53, ascites fluid
Sigma-Aldrich
Anti-RYR2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution